Accueil   Diary - News   All news PDC*line Pharma enters into a licensing agreement with leading Korean pharmaceutical company LG Chem to develop PDC*lung cancer vaccine in Asia

PDC*line Pharma enters into a licensing agreement with leading Korean pharmaceutical company LG Chem to develop PDC*lung cancer vaccine in Asia

 

PDC*line Pharma grants exclusive license in South Korea and exclusive option
in other Asian countries to LG Chem Life Sciences Company, for the
development and commercialization of PDC*lung cancer vaccine for lung cancer

 

Liège, Belgium, Grenoble, France and Seoul, South Korea, March 20, 2019 - PDC*line Pharma, a biotech company developing a new class of potent and scalable antigen presenting cell, based on a proprietary cell line of Plasmacytoid Dendritic cells (PDC*line), announces today that it has signed an exclusive licensing and option agreement with LG Chem Life Sciences Company, the life sciences division of LG Chem Ltd. This agreement, which includes a development and commercialization collaboration agreement, opens new markets to PDC*line Pharma and expands the global footprint of its PDC*line-based cancer vaccine.

 

Read the press release